Senate AWP Plan Directs HHS To Determine “Market Price” For Chemotherapy
Executive Summary
The Senate Finance Committee's Medicare reform bill includes a provision directing HHS to determine actual "market prices" for reimbursement of outpatient drugs currently covered under part B
You may also be interested in...
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says
FDA Generic Rx Reforms Contribute To Medicare Budget Squeeze
CBO is predicting only minor savings to the Medicare prescription drug program through Waxman/Hatch reforms contained in the Senate and House versions of the Medicare bill in light of previous reforms announced by FDA